Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients
NCT03172377
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
174
Enrollment
OTHER
Sponsor class
Conditions
Crohn Disease in Remission
Crohn Disease
Interventions
OTHER:
Lengthening adalimumab dosing interval
Sponsor
Radboud University Medical Center
Collaborators
[object Object]